Cargando…
Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier
In this study, a glycyrrhetinic acid-functionalized mesoporous silica nanoparticle (MSN-GA) was prepared for active tumor targeting. MSN-GA exhibited satisfactory loading capacity for insoluble drugs, uniform size distribution, and specific tumor cell targeting. Glycyrrhetinic acid, a hepatocellular...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476610/ https://www.ncbi.nlm.nih.gov/pubmed/28652738 http://dx.doi.org/10.2147/IJN.S135626 |
_version_ | 1783244621329989632 |
---|---|
author | Lv, Yongjiu Li, Jingjing Chen, Huali Bai, Yan Zhang, Liangke |
author_facet | Lv, Yongjiu Li, Jingjing Chen, Huali Bai, Yan Zhang, Liangke |
author_sort | Lv, Yongjiu |
collection | PubMed |
description | In this study, a glycyrrhetinic acid-functionalized mesoporous silica nanoparticle (MSN-GA) was prepared for active tumor targeting. MSN-GA exhibited satisfactory loading capacity for insoluble drugs, uniform size distribution, and specific tumor cell targeting. Glycyrrhetinic acid, a hepatocellular carcinoma-targeting group, was covalently decorated on the surface of MSN via an amido bond. The successful synthesis of MSN-GA was validated by the results of Fourier transform infrared spectroscopy, transmission electron microscopy (TEM), and zeta potential measurement. TEM images revealed the spherical morphology and uniform size distribution of the naked MSN and MSN-GA. Curcumin (CUR), an insoluble model drug, was loaded into MSN-GA (denoted as MSN-GA-CUR) with a high-loading capacity (8.78%±1.24%). The results of the in vitro cellular experiment demonstrated that MSN-GA-CUR significantly enhanced cytotoxicity and cellular uptake toward hepatocellular carcinoma (HepG2) cells via a specific GA receptor-mediated endocytosis mechanism. The results of this study provide a promising nanoplatform for the targeting of hepatocellular carcinoma. |
format | Online Article Text |
id | pubmed-5476610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-54766102017-06-26 Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier Lv, Yongjiu Li, Jingjing Chen, Huali Bai, Yan Zhang, Liangke Int J Nanomedicine Original Research In this study, a glycyrrhetinic acid-functionalized mesoporous silica nanoparticle (MSN-GA) was prepared for active tumor targeting. MSN-GA exhibited satisfactory loading capacity for insoluble drugs, uniform size distribution, and specific tumor cell targeting. Glycyrrhetinic acid, a hepatocellular carcinoma-targeting group, was covalently decorated on the surface of MSN via an amido bond. The successful synthesis of MSN-GA was validated by the results of Fourier transform infrared spectroscopy, transmission electron microscopy (TEM), and zeta potential measurement. TEM images revealed the spherical morphology and uniform size distribution of the naked MSN and MSN-GA. Curcumin (CUR), an insoluble model drug, was loaded into MSN-GA (denoted as MSN-GA-CUR) with a high-loading capacity (8.78%±1.24%). The results of the in vitro cellular experiment demonstrated that MSN-GA-CUR significantly enhanced cytotoxicity and cellular uptake toward hepatocellular carcinoma (HepG2) cells via a specific GA receptor-mediated endocytosis mechanism. The results of this study provide a promising nanoplatform for the targeting of hepatocellular carcinoma. Dove Medical Press 2017-06-12 /pmc/articles/PMC5476610/ /pubmed/28652738 http://dx.doi.org/10.2147/IJN.S135626 Text en © 2017 Lv et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Lv, Yongjiu Li, Jingjing Chen, Huali Bai, Yan Zhang, Liangke Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier |
title | Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier |
title_full | Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier |
title_fullStr | Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier |
title_full_unstemmed | Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier |
title_short | Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier |
title_sort | glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476610/ https://www.ncbi.nlm.nih.gov/pubmed/28652738 http://dx.doi.org/10.2147/IJN.S135626 |
work_keys_str_mv | AT lvyongjiu glycyrrhetinicacidfunctionalizedmesoporoussilicananoparticlesashepatocellularcarcinomatargeteddrugcarrier AT lijingjing glycyrrhetinicacidfunctionalizedmesoporoussilicananoparticlesashepatocellularcarcinomatargeteddrugcarrier AT chenhuali glycyrrhetinicacidfunctionalizedmesoporoussilicananoparticlesashepatocellularcarcinomatargeteddrugcarrier AT baiyan glycyrrhetinicacidfunctionalizedmesoporoussilicananoparticlesashepatocellularcarcinomatargeteddrugcarrier AT zhangliangke glycyrrhetinicacidfunctionalizedmesoporoussilicananoparticlesashepatocellularcarcinomatargeteddrugcarrier |